Kornimate/medical-research-clean huggingface dataset:
doppler ultrasound in early detection of diabetic nephropathy type 2 diabetes mellitus.

Conditions: Diabetic Nephropathies

Summary: doppler sonography provides an easily applicable, non-invasive, and well-established method for investigating renal morphologic characteristics and measuring vascular resistance in the renal parenchyma. doppler are of strategic importance in providing qualitative and quantitative information about the renal vasculature, which can be obtained through the assessment of the resistive index.

nephropathy is one of the most common long-term, life-threatening complications causing a high rate of morbidity and mortality among individual patients with type 2 diabetes. the onset and progression of nephropathy can be delayed by interventions, provided they are instituted early in the course of the disease. doppler sonography allows non-invasive method for investigating renal hemodynamics. renal resistive index measured using doppler ultrasonography, reflects intra-renal vascular resistance. although doppler sonography clearly does not substitute for renal biopsy, several studies have suggested that it might aid in the management of established renal disease and provide an easily applicable and noninvasive method for investigating renal hemodynamics. doppler sonography provides an easily applicable, non-invasive, and well-established method for investigating renal morphologic characteristics and measuring vascular resistance in the renal parenchyma. doppler are of strategic importance in providing qualitative and quantitative information about the renal vasculature, which can be obtained through the assessment of the resistive index. it is one of the most sensitive parameters in the study of kidney diseases and allows us to quantify the changes in renal plasma flow . a normal resistive index is below 0.7 in adults and children who are six years of age or older.

Eligibility criteria:
inclusion criteria: * 1. type 2 diabetic patients. 2. serum creatinine \<1.2 mg/dl exclusion criteria: - 1. patients with known history of renal disease or any systemic diseases with renal complications. 2. serum creatinine \>1.2 mg/dl
a study to evaluate safety and immunogenicity of apv006 in healthy adults

Conditions: Diphtheria; Tetanus; Pertussis; Poliomyelitis; Hepatitis B; Haemophilus Influenzae Type b Infection

Summary: this is a single-center, randomized, active-controlled, parallel-design, double-blind, phase i study to evaluate the safety and immunogenicity of a single dose of apv006 in healthy adults.


Eligibility criteria:
inclusion criteria: * healthy male and female adults aged 19 - 55 on visit 1 * those without clinically significant abnormalities on the screening test on visit 1 * those with a confirmed bmi of 18.5 kg/m2 to less than 30 kg/m2 on visit 1 * those who have heard a detailed explanation of the study and whose written consent to participate in the study was given voluntarily by themselves or their legal representatives exclusion criteria: * those who participated in other studies and took investigational products/ investigational vaccines within 6 months from visit 1 * those who took tetanus toxoid (tt), tetanus-diphtheria (td), tetanus-reduced diphtheria-acellular pertussis (tdap) vaccine for adults, or other vaccines containing tetanus-diphtheria for adults within 5 years from visit 1 * those who were vaccinated within 4 weeks from visit 1 or who plan to receive vaccines other than the investigational vaccine from the participation in this study to visit 5 * have had diphtheria, tetanus, pertussis, hepatitis b, polio, or invasive diseases caused by haemophilus influenzae type b
harnessing mhealth and social support to improve diabetes related health behavior for inner-city patients

Conditions: Diabetes Mellitus

Summary: in this study, an existing mobile health intervention to improve diabetes self-management will be combined with a social support module and tested for feasibility. the investigators hypothesize that this combination will be feasible and acceptable to both patients and their loved ones.

this will be the first ever evaluation of a highly scalable and low-cost social support intervention for patients with diabetes delivered entirely via mobile phones. text-med fans (trial to examine text-based mhealth for emergency department patients with diabetes with family and friend network supporter) will unite the benefits of mhealth (scalability, ease of access) and social support interventions (personalized motivation, emotional support). the diabetes fans text message based curriculum will make it easier for friends and family to become supporters. additionally, augmenting text-med with the fans social support module will be more effective than text-med alone. the personalized support of text-med fans will also be more effective than providing text-med in combination with a community health worker supporter who lacks a pre-existing relationship with the patient. through this innovative combination, i can create a more cost-effective and diffusible mhealth solution that maintains the personal connection of social support interventions. to date there has only been one study evaluating social support interventions for patients with diabetes using mhealth, but in this study participants were paired with other subjects with diabetes (not friends or family) and it required intensive face-to-face support group time. text-med fans will provide key insights into the utility of combining social support interventions delivered solely via mhealth in low-income latino patients. these insights will help future interventions achieve maximal impact on diabetes and other chronic disease management.

Eligibility criteria:
inclusion criteria: * type ii diabetes * hba1c \>or=8 at enrollment * speak english or spanish * has support person willing to participate exclusion criteria: * unable to consent * pediatric patient

Keywords: hispanic americans cellular phone behavior
pharmacokinetics of vitamin d in multiple sclerosis and in health

Conditions: Multiple Sclerosis, Relapsing-remitting

Summary: this is a pilot study of oral vitamin d supplementation to determine if patients with multiple sclerosis (ms) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin d levels. the investigators will also assess whether the immunologic or relevant gene expression response to oral vitamin d supplementation differs in patients with ms and healthy controls.


Eligibility criteria:
inclusion criteria: * female * healthy or multiple sclerosis * aged 18 to 60 * body mass index is between 18 kg/m2 and 30 kg/m2 * screening 25-hydroxyvitamin d level ≤ 75 nmol/l (30 ng/ml) * white race * non-hispanic ethnicity * willing to use birth control during study * willing to not use tanning bed during study if subject has multiple sclerosis: * relapsing-remitting ms, as defined by mcdonald 2005 criteria * screening expanded disability status scale score ≤ 3.0 * using no medication for ms, or taking copaxone, (glatiramer acetate), interferons, or natalizumab exclusion criteria: * pregnant or nursing * taking multivitamin \& unwilling to remain off it during study * taking cod liver oil \& unwilling to remain off it during study * on a fat-restricted diet * history of renal disease or nephrolithiasis (kidney stones) * history of liver disease * taking thiazide diuretics * history of hyperthyroidism * history of infection with mycobacterium species * history of sarcoidosis * history of cancer * history of cardiac disease * history of hiv * history of gastrointestinal disorder * taking medications that interfere with gastrointestinal absorption * cigarette smoker in past month * use of illicit drugs in past month * use of steroids in past month * history of hypercalcemia, and screening serum calcium ≤ 10 mg/dl (ucsf) or ≤ 10.7 mg/dl (johns hopkins) * history of hypercalciuria * evidence of anemia (hgb \<11.0 g/dl) * history of other serious medical conditions * taking medications that involve the p450 system or may interact with vitamin d (digoxin, diltiazem, verapamil, cimetidine, heparin, or low-molecular weight heparin) * other concerns about safety from the perspective of the treating physician if subject has ms: -history of major heat sensitivity (leading to sun-avoidant behaviors)

Keywords: multiple sclerosis healthy controls pharmacokinetics vitamin d
microarray application in newborns with multiple congenital anomalies

Conditions: Multiple Abnormalies

Summary: objective: congenital anomalies are defined as abnormalities of body structure or function that are present at birth and have developed prenatally. microarray is considered the first-tier diagnostic test for patients with multiple congenital anomalies. the aim of this study is to determine the relationship between microarray results and the phenotype in newborns with multiple congenital anomalies, contribute to patient management by comparing with similar cases in the literature, detect previously unidentified copy number variations (cnv), investigate the hereditary origin of the detected changes, and provide appropriate genetic counseling.

method: between december 2022 and november 2023, newborns with multiple congenital anomalies requiring follow-up and treatment in the neonatal intensive care unit of konya city hospital were evaluated. newborns with examination findings suggesting a recognizable numerical chromosome anomaly or a history of teratogenicity were excluded from the study. newborns with two major or one major and two minor, or three or more minor congenital anomalies were included. microarray studies were performed on patients who met the inclusion criteria. cnvs identified were examined in relevant databases, and pathogenicity was assessed. detected alterations were compared with the clinical findings in the patient database.

Eligibility criteria:
inclusion criteria: * newborns with two major or one major and two minor, or three or more minor congenital anomalies were included exclusion criteria: * newborns with examination findings suggesting a recognizable numerical chromosome anomaly * history of teratogenicity

Keywords: newborn multipl congenital anomalies microarray copy number variant
neural mechanisms of meditation training in healthy and depressed adolescents: an mri connectome study

Conditions: Healthy

Summary: the primary objective will be to study changes in putamen structural connectivity in healthy teens with meditation training. hypothesis: putamen structural node strength will increase in the training group compared to controls. r61 go/no-go criteria. detect an effect size (a threshold of cohen's d \> 0.20) in changes of the primary mechanistic outcome (putamen structural node strength) by the described meditation training in 100 healthy adolescents that are 14-18 years old and retain at least 80% of randomized participants for primary outcome measurement at the end of the study regardless of adherence to the intervention. the secondary objective will be to study changes in emotional problems in healthy teens with meditation training. hypothesis: there will be a significant decrease in emotional problems measured with the strengths and difficulties questionnaire (sdq) in the training group compared to controls. design and outcomes: the current research study design will utilize an individually randomized group treatment, open-label, waitlist-controlled clinical trial to test the efficacy and safety of the investigator's innovative mindfulness meditation intervention (training for awareness resilience and action \[tara\]) on the primary outcome (putamen structural node strength) and secondary outcome (emotional problems measured with the strengths and difficulties questionnaire \[sdq\]) in healthy adolescents between the ages of 14 to 18 years old.


Eligibility criteria:
inclusion criteria: * healthy female and male adolescents, 14-18 years old * fluency in english exclusion criteria: * subjects younger or older than 14-18 years old. * subjects who are not healthy. subjects who are taking any psychotropic medication. * mri contraindications (ferromagnetic objects on or inside the body, e.g., braces) and pregnancy. * not allowable: current mindfulness training (e.g. mbsr, mbct, dbt) and/or practice with a typically sitting meditation or yoga of 20 or more minutes two or more times per week within 60 days prior to study entry. * potential adolescent subjects with current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to the study requirements will be excluded and not allowed to enter the study. * potential subjects with an inability or unwillingness to give written informed assent or whose legal guardian/representative are unable or unwilling to give written informed consent will be excluded and not allowed to enter the study.
internet-based behavioural parent training intervention for children with attention deficit/hyperactivity disorder

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)

Summary: this study aims to investigate the effectiveness of an internet-based behavioural parent training intervention on children's adhd symptoms and children's and parents' mental health status.

the study design was a 2-parallel-group experimental longitudinal study. firstly, the children received a diagnostic interview by an experienced child and adolescent psychiatrist at wuhan mental health centre for confirmation of inclusion and exclusion criteria. parents who were eligible for the inclusion criteria and interested in the internet-based behavioural parent training (i-bpt) program were recruited. after the assessments of adhd symptoms and psychiatric comorbidity, participants were randomly assigned in a 1:1 ratio to either the routine clinical care (rcc) group or i-bpt+rcc group using computer-generated randomization numbers. participants in the i-bpt+rcc group were offered 2 months (8 weeks) of internet-assisted parent training in addition to routine outpatient treatment. the rcc group initially received only routine outpatient treatment, yet, after post-follow-up assessment, they were provided with the same i-bpt intervention for ethical considerations. both groups were followed up after intervention by electronic questionnaire.

Eligibility criteria:
inclusion criteria: * 1.meeting the diagnostic criteria for adhd in diagnostic and statistical manual of mental disorders, fifth edition * 2.total iq greater than 70 as measured by the wechsler intelligence scale for children, fourth edition (wisc-iv) * 3.child and their parents consent to the study exclusion criteria: * 1.children or parents with severe organic encephalopathy and other severe mental disorders * 2.has received or is receiving behavioral treatment (parent training) * 3.parents who could not understand or lacking of access to computers and the internet

Keywords: attention deficit hyperactivity disorder
sphingosine-1 phosphate -receptor targeting and microglial activation

Conditions: Multiple Sclerosis

Summary: to evaluate the usability of positron emission tomography imaging as a novel outcome measure in multiple sclerosis studies

background and rationale in multiple sclerosis (ms), significant pathology correlating to disease progression, to expanded disability status scale (edss) and to cognitive decline, takes place outside the plaque areas, i.e. in areas of normal appearing white matter and gray matter. neuropathological studies suggest that mechanisms involved in this widespread pathology include activation of microglial cells, oxidative stress and deficiency in mitochondrial functions. activated microglia can be detected in vivo with a translocator protein (tspo), expressed in activated, but not resting microglia) binding radioligands and positron emission tomography (pet). 11carbon-pk11195 radioligand is one such radioligand. importantly, the possible effect of ms therapies on microglial activity can be evaluated in patients in vivo with pet-imaging performed before and after the treatment.

Eligibility criteria:
inclusion criteria: having signed the informed consent of the investigator-initiated pet study * age 18 - 58 years at the time of informed consent. * ms according to poser or mcdonald criteria * edss score from 0.0 to 6.5. * moderate to heavy lesion load ( \>9 t2 lesions) in mri exclusion criteria: * - patients with other neurodegenerative disease than ms * disease modifying therapy (dmt) within 4 weeks of imaging * corticosteroid treatment within 4 weeks of imaging * patients with significant abnormal findings other than ms in the screening mri. * patients with claustrophobia, or a history of moderate to severe anxiety disorder or panic attacks (which could potentially lead to preterm termination of the imaging) * contraindication to pet scan investigations * exposure to experimental radiation in the past 12 months such that radiodosimetry limits would be exceeded by participating in this study. * intolerance to previous pet scans; i.e. previous hypersensitivity reactions to any pet ligand or imaging agent or failure to participate in and comply with previous pet scans.
an investigational study of bgb-58067 in participants with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of bgb-58067 as monotherapy in participants with advanced solid tumors and with methylthioadenosine phosphorylase (mtap) deficiency.

bgb-58067 is a new drug designed to target a specific protein called protein arginine methyltransferase 5 (prmt5). this protein is involved in many cell activities and can promote cancer growth when it is overactive. high levels of prmt5 are linked to poor outcomes in several types of cancer. this new study will check how safe and helpful a potential anticancer drug called bgb-58067 is. this drug will be tested as monotherapy in participants with advanced solid tumors and with mtap deficiency.

Eligibility criteria:
inclusion criteria: * participants must sign the icf and be capable of giving written informed consent * eastern cooperative oncology group (ecog) performance status of 0 or 1 or karnofsky performance scale (kps) ≥ 70 * life expectancy ≥ 3 months * evidence of homozygous loss of mtap or lost mtap expression in the tumor tissue * able to provide tumor sample to meet the minimum tissue requirement for central mtap deficiency testing * participants with advanced, metastatic, or unresectable solid tumors, who have previously received standard systemic therapy or for whom treatment is not available or not tolerated * adequate organ function exclusion criteria: * prior treatment with any prmt5 inhibitor or methionine adenosyltransferase 2a (mat2a) inhibitor * active leptomeningeal disease or symptomatic spinal cord compression * uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage * any malignancy ≤ 2 years before first dose of study drug except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively * significantly impaired pulmonary function * clinically significant infections * serologically active hepatitis b or c infection * known hiv infection * high cardiovascular risk factors * qtcf \> 470 ms based on the screening triplicate 12-lead ecg records * toxicities (because of prior anticancer therapy) that have not recovered to baseline or stabilized * participants who are unable to swallow or with disease/procedure significantly affecting gastrointestinal function * female participants who are pregnant or are breastfeeding * concurrent participation in another therapeutic clinical study (participation in observational or noninterventional studies is allowed) note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: advanced solid tumor bgb-58067 mtap deficiency
correlation between partial oxygen pressure and oxygen reserve index

Conditions: COLON CANCER

Summary: oxygen reserve index (ori) measured by multiple wave pulse co-oximeter is a new technological development in medical science. our aim in this study is to identify the correlation between arterial oxygen pressure (pao2) and ori, and to identify the specificity and sensitivity of ori as a tool to prevent hypoxia and hyperoxia in abdominal surgery patients.

patients aged between 20-55 years old,american society of anesthesiologists physical status 1-2 who will have hemicolectomy will be included to the study. if hemodynamic instability or a sudden decrease in oxygen saturation by pulse oximetry (spo2) occurs, arterial blood gas analysis will be taken from the patient and ori, spo2, pao2, and arterial oxygen saturation (sao2) will be recorded. the primer endpoint of the study is to identify the correlation between pao2 and ori, seconder end-point is to identify the specificity and sensitivity of ori as a detector of pao2. pearson test for correlation, regression analysis for sensitivity and specificity will be performed. the study will include 240 patients according to power analysis

Eligibility criteria:
inclusion criteria: * patients aged between 20-55 years old * american society of anesthesiologists physical status i-ii * patients undergoing hemicolectomy exclusion criteria: * chronic obstructive and restrictive pulmonary disease * diabetes mellitus * ischemic heart disease * peripheric artery disease. * operations longer than 200 minutes, requirement transfusion of more than 1 u erythrocyte suspension, and requirement of vasopressor or inotrope infusion will be excluded from the study

Keywords: oxygen reserve index, partial oxygen pressure, hemicolectomy
opioid-free total hip arthroplasty

Conditions: Hip Osteoarthritis

Summary: the primary objective of investigators' proposed study is to demonstrate that the following two cohorts undergoing total hip arthroplasty will have equivalent visual analog scale (vas) scores up to 3 months post-operatively: one that is administered a modified multimodal analgesic pathway without opioids and the other administered the current standard multimodal analgesic pathway used at johns hopkins bayview hospital (which includes opioids). the secondary objective is to demonstrate that these cohorts will also have equivalent functional outcomes as determined by both objective measures (such as hip range of motion) and patient-reported outcome measures, such as the hip disability and osteoarthritis outcome score (hoos) and the university of california at los angeles (ucla) activity score.


Eligibility criteria:
inclusion criteria: * patients of all ages with end-stage primary hip osteoarthritis. exclusion criteria: * patients with creatinine clearance between 30 and 60 ml/min * use of any opioid analgesics in the 6 months preceding surgery * revision total hip arthroplasty * patients with liver insufficiency * patients on chronic anticoagulation * workers compensation patients * patients who cannot receive acetaminophen, ketorolac, celecoxib, or gabapentin for any reason (e.g. allergies)